Brief: Cue Biopharma Doses First Patient In Phase 1 Study Of Cue-102 For Wilms' Tumor 1 (Wt1) - Expressing Cancers

Cue Biopharma

22/08/2022 13:16

Aug 22 (Reuters) - Cue Biopharma Inc  CUE.O :
    * CUE BIOPHARMA DOSES FIRST PATIENT IN PHASE 1 STUDY OF
CUE-102
FOR WILMS’ TUMOR 1 (WT1) - EXPRESSING CANCERS

Source text for Eikon:  ID:nGNX9PcZZL 
Further company coverage:  CUE.O 

 ((Reuters.Briefs@thomsonreuters.com;))